Publications
Detailed Information
Nitric oxide synthase gene polymorphisms and prostate cancer risk
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kyoung-Mu | - |
dc.contributor.author | Kang, Daehee | - |
dc.contributor.author | Park, Sue Kyung | - |
dc.contributor.author | Berndt, Sonja I. | - |
dc.contributor.author | Chatterjee, Nilanjan | - |
dc.contributor.author | Huang, Wen-Yi | - |
dc.contributor.author | Hayes, Richard B. | - |
dc.contributor.author | Chanock, Stephen | - |
dc.contributor.author | Reding, Douglas | - |
dc.date.accessioned | 2012-06-08T07:45:34Z | - |
dc.date.available | 2012-06-08T07:45:34Z | - |
dc.date.issued | 2009-04 | - |
dc.identifier.citation | CARCINOGENESIS; Vol.30 4; 621-625 | ko_KR |
dc.identifier.issn | 0143-3334 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76925 | - |
dc.description.abstract | Nitric oxide (NO) induces cytotoxicity and angiogenesis, and may play a role in prostate carcinogenesis, potentially modulated by environmental exposures. We evaluated the association of prostate cancer with genetic polymorphisms in two genes related to intracellular NO: NOS2A [inducible nitric oxide synthase (NOS); -2892T > C, Ex16 + 14C > T (S608L), IVS16 + 88T > G and IVS20 + 524G > A] and NOS3 [endothelial NOS; IVS1 - 762C > T, Ex7 - 43C > T (D258D), IVS7 - 26A > G, Ex8 - 63G > T (E298D) and IVS15 - 62G > T]. Prostate cancer cases (n = 1320) from the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial were frequency matched to controls (n = 1842), by age, race, time since initial screening and year of blood draw. An antioxidant score [range 3-12; low (3-7) versus high (8-12)] was created by summing the quartile levels of vitamin E, beta-carotene and lycopene, which were coded from 1 to 4, respectively. The global tests for all eight single-nucleotide polymorphisms (SNPs) (excluding NOS2A -2892T > C, with low minor allele frequency) were statistically significant for prostate cancer (P = 0.005), especially for aggressive cancer (stage III-IV or Gleason score >= 7) (P = 0.01). The NOS2A IVS16 + 88 GT/TT was associated with increased prostate caner risk (odds ratio = 1.24, 95% confidence interval = 1.00-1.54), whereas the IVS20 + 524 AG/GG was associated with decreased risk (0.77, 0.66-0.90). The NOS3 IVS7 - 26GG was associated with increased prostate caner risk (1.33, 1.07-1.64). All these SNPs showed significant associations with aggressive cancer and not for non-aggressive cancer. In the evaluation of effect modification, the effect of the NOS2A IVS16 + 88 GT/TT on aggressive cancer was stronger among subjects with higher antioxidant intake (1.61, 1.18-2.19; P(interaction) = 0.01). Our results suggest that NOS gene polymorphisms are genetic susceptibility factors for aggressive prostate cancer. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | OXFORD UNIV PRESS | ko_KR |
dc.title | Nitric oxide synthase gene polymorphisms and prostate cancer risk | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이경무 | - |
dc.contributor.AlternativeAuthor | 강대희 | - |
dc.contributor.AlternativeAuthor | 박수경 | - |
dc.identifier.doi | 10.1093/carcin/bgp028 | - |
dc.citation.journaltitle | CARCINOGENESIS | - |
dc.description.citedreference | Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91 | - |
dc.description.citedreference | Duggan D, 2007, J NATL CANCER I, V99, P1836, DOI 10.1093/jnci/djm250 | - |
dc.description.citedreference | Lee KM, 2007, BREAST CANCER RES TR, V106, P433, DOI 10.1007/s10549-007-9506-y | - |
dc.description.citedreference | Zheng SL, 2007, J NATL CANCER I, V99, P1525, DOI 10.1093/jnci/djm169 | - |
dc.description.citedreference | Kang D, 2007, CANCER EPIDEM BIOMAR, V16, P1581, DOI 10.1158/1055-9965.EPI-07-0160 | - |
dc.description.citedreference | Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022 | - |
dc.description.citedreference | Cronauer MV, 2007, ONCOGENE, V26, P1875, DOI 10.1038/sj.onc.1209984 | - |
dc.description.citedreference | Ng QS, 2007, LANCET ONCOL, V8, P111, DOI 10.1016/S1470-2045(07)70001-3 | - |
dc.description.citedreference | Lancaster JR, 2006, CANCER RES, V66, P6459, DOI 10.1158/0008-5472.CAN-05-2900 | - |
dc.description.citedreference | Packer BR, 2006, NUCLEIC ACIDS RES, V34, pD617, DOI 10.1093/nar/gkj151 | - |
dc.description.citedreference | Lim HW, 2005, EXP MOL MED, V37, P497 | - |
dc.description.citedreference | Parnes HL, 2005, J CLIN ONCOL, V23, P368, DOI 10.1200/JCO.2005.08.027 | - |
dc.description.citedreference | Tong X, 2004, CANCER LETT, V210, P63, DOI 10.1016/j.canlet.2003.12.021 | - |
dc.description.citedreference | Wartenberg M, 2003, INT J CANCER, V104, P274, DOI 10.1002/ijc.10928 | - |
dc.description.citedreference | Medeiros R, 2003, CANCER LETT, V189, P85 | - |
dc.description.citedreference | Veldman BA, 2002, J HYPERTENS, V20, P2023 | - |
dc.description.citedreference | Hefler LA, 2002, GYNECOL ONCOL, V86, P134, DOI 10.1006/gyno.2002.6749 | - |
dc.description.citedreference | Medeiros R, 2002, EUR J CANCER PREV, V11, P343 | - |
dc.description.citedreference | Schaid DJ, 2002, AM J HUM GENET, V70, P425 | - |
dc.description.citedreference | Wink DA, 2001, ANTIOXID REDOX SIGN, V3, P203 | - |
dc.description.citedreference | UOTILA P, 2001, UROL RES, V29, P23 | - |
dc.description.citedreference | Klotz T, 1998, CANCER, V82, P1897 | - |
dc.description.citedreference | Wink DA, 1998, CARCINOGENESIS, V19, P711 | - |
dc.description.citedreference | LALA PK, 1998, CANCER METAST REV, V81, P889 | - |
dc.description.citedreference | TIPPETT KS, 1997, CONTINUING SURVEY FO | - |
dc.description.tc | 7 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.